[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-381876-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-381876-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","genomic-profiling-for-non-small-cell-lung-cancer-clinical-relevance-in-staging-and-prognosis","Genomic profiling for non-small cell lung cancer - Clinical relevance in staging and prognosis","","Lung cancer remains highly prevalent, with non-small cell lung cancer (NSCLC) accounting for roughly 80% of cases, driving substantial mortality due to frequent recurrence. Conventional staging improves risk stratification for adjuvant chemotherapy selection, yet genomic approaches can refine patient risk classification. Gene expression profiling offers a comparative advantage by grouping patients into high- and low-risk categories, guided by expression of genes linked to proliferative pathways. This narrative review evaluates evidence supporting genomic profiling for NSCLC prognosis.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/genomic-profiling-for-non-small-cell-lung-cancer-clinical-relevance-in-staging-and-prognosis/381876/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/genomic-profiling-for-non-small-cell-lung-cancer-clinical-relevance-in-staging-and-prognosis/381876.png","ImageObject",300,407,{"name":42,"@type":43},"Ben ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is genomic profiling important in non-small cell lung cancer (NSCLC)?","Question",{"text":63,"@type":64},"Genomic profiling can improve patient risk classification for treatment decisions and prognostic assessment, especially given NSCLC’s high recurrence and mortality rates.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do gene expression analyses help risk stratification in NSCLC?",{"text":68,"@type":64},"They use expression patterns of genes involved in proliferative pathways to categorize patients into high- and low-risk groups for outcomes such as prognosis.",{"name":70,"@type":61,"acceptedAnswer":71},"What challenge do conventional staging systems address in NSCLC?",{"text":72,"@type":64},"Conventional staging helps classify patient risk to simplify selection for adjuvant chemotherapy, but genomic signatures can provide additional advantages in risk characterization.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},381876,1790862772,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":33,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":124},2336478951081,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","®  \n Narrative Review   \nGenomic profiling for non-small cell lung cancer Clinical relevance in staging and prognosis  \nAbhinav Bhattarai, BSca, Sangam Shah, MBBSa,*  , Hashem Abu Serhan, MDb, Ranjit Sah, MDc,d,e, Sanjit Sah, MDf,g  \n\n| Abstract\u003Cbr>Lung cancer is one of the most common cancers prevalent and around 80% of all cases are non-small cell lung cancer (NSCLC) . Due to high recurrence rates, the mortality of NSCLC is high. Conventional staging systems allowed risk classification of patients in order to simplify the patient selection for adjuvant chemotherapy. Gene expression analysis has been shown to possess advantage over conventional staging systems in NSCLC in terms of patients risk classification. This article reviews the evidenceson the genomic profiling of NSCLC patients into high and low-risk groups based on the expression of genes involved in various proliferative pathways. |\n| --- |\n| Abbreviations: DFS = disease-free survival, NCCN = National Comprehensive Cancer Network , NSCLC = non-small cell lung cancer, TKIs = Tyrosine Kinase Inhibitors, TNM = tumor node metastasis. |\n| Keywords: chemotherapy, NSCLC, profiling, prognosis, risk |\n\n1. Introduction  \nThe capability of genomic testing is growing to provide greater benefits for patients and healthcare systems in the context of personalized medicine, which is currently undergoing change. By leveraging extensive and carefully maintained genetic databases and generating evidence to guide testing methodologies, treatment alternatives, and associated clinical decision support, increased genomic testing deployment can enhance clinical value. The use of genomic mutational-methylation signatures in cancers has been widespread for the past decade. While multigene assays have increasingly received FDA approval and are now incorporated into cancer screening protocols, several other signatures are undergoing trials and have shown promising results. Currently, BreastNext, MammaPrint, and Oncotype DX have been widely employed in the risk characterization of breast cancers.[1–3] As such, ConfirmMDx, ExoDx for prostate cancer[4,5] and Epi proColon, ColoVantage for colorectal cancer have been widely recognized genomic signatures.[6,7] Additionally, these signatures have significantly aided in therapeutic indication, determining prognostic trajectory, and importantly, making decisions.  \nLung cancer has been recognized as one of the commonest cancers prevalent today. In 2020, lung cancer was ranked second position on the list of worldwide cancer prevalence with 2.2 million new cases and the numbers have been outrageously  \nskyrocketing. Lung cancer is the most prevalent cancer type in men and the second most prevalent cancer after breast cancer in women. Approximately, 12.5% of all cancer patients have lung cancer. Despite the development of advanced diagnostic tools and treatment options, lung cancer still is the leading cause of cancer deaths.[8]  \nNon-small cell lung cancer (NSCLC) is a more frequent subtype that comprises around 80% of all lung cancer cases and is known for its poor prognosis and high mortality rate inpatients. Different types of NSCLC: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma have been identified.[9] These tumors have a disastrously high recurrence rate ranging from 35% to 50%, making them one of the most difficult cancers to treat. Despite surgical resection of the tumor, a 5-year mortality rate of 30% to 50% in patients diagnosed with Stage I–IIA NSCLC has been reported and in the last 30 years, there has been very minimal progress in patient survival. This high mortality has been attributed to widespread distant metastases and recurrence. Interestingly, research has found that the timely administration of adjuvant duplet cisplatin-based chemotherapy can enhance the 5-year survival rates by 4% to 15% in these patients.[10,11] It is therefore paramount to identify the patients who fall within this 30% to 50% category of high ri","cbCaitOmy5LoE1Ud","https://ap.wps.com/l/cbCaitOmy5LoE1Ud","pdf",548619,"English","# Abstract\n# Abbreviations\n# Introduction","[{\"question\":\"Why is genomic profiling important in non-small cell lung cancer (NSCLC)?\",\"answer\":\"Genomic profiling can improve patient risk classification for treatment decisions and prognostic assessment, especially given NSCLC’s high recurrence and mortality rates.\"},{\"question\":\"How do gene expression analyses help risk stratification in NSCLC?\",\"answer\":\"They use expression patterns of genes involved in proliferative pathways to categorize patients into high- and low-risk groups for outcomes such as prognosis.\"},{\"question\":\"What challenge do conventional staging systems address in NSCLC?\",\"answer\":\"Conventional staging helps classify patient risk to simplify selection for adjuvant chemotherapy, but genomic signatures can provide additional advantages in risk characterization.\"}]","Genomic profiling for non-small cell lung cancer - Clinical relevance in staging and prognosis | PDF",1790247553]